• Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.

• Female subjects aged 18 to 75 years (including 18 and 75 years).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Histologically confirmed recurrent or metastatic cervical cancer (squamous cell, HPV-associated adenocarcinoma, or adenosquamous), not amenable to resection or chemoradiation with curative intent.

• Subject must have received a platinum-based chemotherapy with or without bevacizumab and received no more than 2 prior systemic therapy in the metastatic/recurrent setting. Subject must have experienced radiographic progression during or after the last treatment regimen.

• An archival tumor tissue sample or a fresh tissue sample should be provided.

• Life expectancy of ≥ 12 weeks.

• Subjects must have measurable disease according to RECIST (version 1.1).

• Adequate to receive one of the chemotherapy regimens in the control group (gemcitabine, pemetrexed, topotecan);

⁃ Adequate organ functions.

⁃ Sexually active fertile subjects must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.

⁃ Subjects are willing to follow study procedures.